



Statement About the Edwards Unilateral Pro-Innovation Policy (“UPIP”)

Edwards Lifesciences’ Unilateral Pro-Innovation Policy published in 2019 is no longer applicable and has been removed from the company’s policies. This action was taken in connection with an investigation conducted by the European Commission’s Directorate-General for Competition.

As the pioneer in structural heart innovation, Edwards is dedicated to addressing the unmet needs of structural heart patients worldwide through the development of breakthrough therapies, as well as to clinical study, research, and evidence generation.

Edwards is committed to free and fair competition in the structural heart space and to the advancements made possible by innovation competition and the protection of intellectual property rights and trade secrets.

Effective date: February 13, 2026